Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
REPH - Recro Pharma Inc
$2.97
0.01(0.34%)9:00:00 PM 1/15/2021
Recro Pharma, Inc. a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products to pharmaceutical market in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Stock Chart

Summary:

  • Volatility is at a recent 2 week low. A recent low volatility of stock movement within a box range could trigger break through when activities pick up.
  • A moving average of short volume ratio is at a recent 2 week low. A lower short volume ratio could be a bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Stock news

    12/19/2020REPH
    Recro Grants Inducement Award to New Chief Executive Officer

    MALVERN, Pa., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that it granted an inducement award to its newly-appointed President and Chief Executive Officer, David Enloe. The award consists of 217,822 restricted stock un...

    12/16/2020REPH
    Recro Announces Executive Changes

    David Enloe Named President and Chief Executive OfficerMALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of ...

    12/15/2020REPH
    Is the Options Market Predicting a Spike in Recro Pharma (REPH) Stock?

    Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.

    12/15/2020REPH
    Is REPH A Good Stock To Buy Now?

    While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious towards the current bull run since March and hedging or reducing many of their long positions. Some fund managers are betting on Dow hitting […]

    12/11/2020REPH
    Oppenheimer Says These 2 Stocks Could Spike Over 100%

    Markets have been turning mostly up since the election, as investors have taken the measure of the macro environment and appear pleased. There is some expectation that political matters may settle down, allowing government, public health officials, and the business world to focus on beating the next wave of the coronavirus pandemic.The big news on that front, of course, came from Pharma giants Pfizer and Moderna, which have both announced success in trial phases of COVID vaccines, and are curren...

    11/11/2020REPH
    How Much Is Recro Pharma's (NASDAQ:REPH) CEO Getting Paid?

    Gerri Henwood has been the CEO of Recro Pharma, Inc. (NASDAQ:REPH) since 2008, and this article will examine the...

    11/9/2020REPH
    Recro Pharma (REPH) Q3 2020 Earnings Call Transcript

    Good morning, and thank you for joining us on today's conference call to discuss Recro's third-quarter 2020 financial results. Following prepared remarks today by Gerri and Ryan, we will open the call for questions. Before we begin our formal comments, I'll remind you that various remarks we make today constitute forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements related to our financial outlook.